High dose methotrexate (HD-MTX) prophylaxis is not associated with a reduction in CNS relapse in high risk patients with aggressive B-cell lymphoma. Speaking at ASH 2021, Dr Katharine Lewis said CNS relapse was an uncommon but devastating complication of aggressive B-cell lymphoma with a median overall survival (OS) of less than six months. Dr Lewis, ...
Time to reconsider methotrexate prophylaxis for CNS relapse in lymphoma
By Mardi Chapman
13 Jan 2022